 | This article has multiple issues. Please help
improve it or discuss these issues on the
talk page. (
Learn how and when to remove these template messages)
|
Biostrophin is a drug which may serve as a vehicle for gene therapy, in the treatment of Duchenne and Becker muscular dystrophy. [1]
As mutations in the gene which codes for the protein dystrophin is the underlying defect responsible for both disorders, biostrophin will deliver a genetically-engineered, functional copy of the gene at the molecular level to affected muscle cells. [1] Dosage, as well as a viable means for systemic release of the drug in patients, is currently being investigated with the use of both canine and primate animal models. [2]
Biostrophin is being manufactured by Asklepios BioPharmaceuticals, Inc., with funding provided by the Muscular Dystrophy Association. [3]
See also
Other drugs for Duchenne muscular dystrophy
- Ataluren
- Rimeporide (experimental)
References
- ^ a b Khurdayan VK, Bozzo J, Prous JR (Oct 2005). "Chronicles in drug discovery". Drug News & Perspectives. 18 (8): 517–522. doi: 10.1358/dnp.2005.18.8.953409. ISSN 0214-0934. PMID 16391721.
- ^ http://www.ncbiotech.org/news_and_events/industry_news/duchenne.html Dec 2006 Archived October 17, 2007, at the Wayback Machine
- ^ "Asklepios Biopharmaceutical, Inc. Announces Cross License with GlaxoSmithKline". 2006-09-28.
External links
 | This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it. |
 | This genetics article is a stub. You can help Wikipedia by expanding it. |
 | This article about biological engineering is a stub. You can help Wikipedia by expanding it. |
| This article has multiple issues. Please help
improve it or discuss these issues on the
talk page. (
Learn how and when to remove these template messages)
|
Biostrophin is a drug which may serve as a vehicle for gene therapy, in the treatment of Duchenne and Becker muscular dystrophy. [1]
As mutations in the gene which codes for the protein dystrophin is the underlying defect responsible for both disorders, biostrophin will deliver a genetically-engineered, functional copy of the gene at the molecular level to affected muscle cells. [1] Dosage, as well as a viable means for systemic release of the drug in patients, is currently being investigated with the use of both canine and primate animal models. [2]
Biostrophin is being manufactured by Asklepios BioPharmaceuticals, Inc., with funding provided by the Muscular Dystrophy Association. [3]
See also
Other drugs for Duchenne muscular dystrophy
- Ataluren
- Rimeporide (experimental)
References
- ^ a b Khurdayan VK, Bozzo J, Prous JR (Oct 2005). "Chronicles in drug discovery". Drug News & Perspectives. 18 (8): 517–522. doi: 10.1358/dnp.2005.18.8.953409. ISSN 0214-0934. PMID 16391721.
- ^ http://www.ncbiotech.org/news_and_events/industry_news/duchenne.html Dec 2006 Archived October 17, 2007, at the Wayback Machine
- ^ "Asklepios Biopharmaceutical, Inc. Announces Cross License with GlaxoSmithKline". 2006-09-28.
External links
|
| This drug article relating to the musculoskeletal system is a stub. You can help Wikipedia by expanding it. |
|
| This genetics article is a stub. You can help Wikipedia by expanding it. |
|
| This article about biological engineering is a stub. You can help Wikipedia by expanding it. |